Swiss pharmaceutical giant Novartis has announced it has exercised the option to license its right to develop and commercialise TQJ230, a targeted cardiovascular (CV) therapy, from Akcea Therapeutics’ affiliate Ionis...
25 February 2019
25 February 2019 News
Global pharmaceutical company AstraZeneca has announced its drug Brilinta (ticagrelor) in combination with aspirin has met its primary endpoint, a statistically significant reduction in major adverse cardiovascular events, in the...
13 February 2019 Analysis
February is National Heart Month in the UK and the US, which focuses on raising awareness of heart disease. Often caused by emotional distress, takotsubo cardiomyopathy is a rare heart...
11 February 2019 News
Regeneron and Sanofi have announced they have lowered the list price of high cholesterol drug Praluent (alirocumab) in the US by approximately 60%.
28 November 2018 News
Swiss firm Roche Group’s affiliate Genentech has agreed to acquire US biotechnology company Jecure Therapeutics to strengthen its position in the treatment of liver diseases.
20 November 2018 Analysis
Heart disease is one of the leading causes of death in men and women, but women are commonly underrepresented in clinical trials. Could this negatively impact the treatment of female...
5 October 2018 Comment
The Asia-Pacific market for heart failure therapeutics was estimated at $733.7 million in 2017 and is projected to reach $1,435.9 million in 2024, increasing at a compound annual growth rate...
20 September 2018 projects
Germany-based pharmaceutical company, Boehringer Ingelheim, is constructing a new tablet production facility in Ingelheim, Germany, with an estimated investment of more than €85m ($97.2m).
18 September 2018 News
Monash University in Australia has reported initial results from a large clinical trial (ASPREE) performed to investigate the benefits and risks of low, daily doses of aspirin in healthy people...
28 August 2018 News
A new phase III clinical trial has demonstrated that Pfizer’s tafamidis drug can lower the risk of death in patients suffering from rare heart condition transthyretin amyloid cardiomyopathy.